Leerink Swann Starts Transcept Pharmaceuticals (TSPT) at Outperform; Advancing in Insomnia

June 4, 2012 8:10 AM EDT
Get Alerts TSPT Hot Sheet
Price: $1.70 --0%

Rating Summary:
    3 Buy, 4 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 10
Trade TSPT Now!
Join SI Premium – FREE
Leerink Swann initiates coverage on Transcept Pharmaceuticals (NASDAQ: TSPT) with a Outperform. PT range $13-$14.

Analyst, Jason M. Gerberry, said, "We see TSPT as well positioned to benefit from the recent launch of Intermezzo, the first drug approved for the treatment of middle of the night (MOTN) insomnia. Epidemiology data suggest a large population of patients suffer from MOTN insomnia, an underserved segment of the market according to MEDACorp physician key opinion leaders (KOLs), who expect Intermezzo to capture significant market share based on the drug's unique activity profile. Also, based on our checks with a MEDACorp patent specialist, we believe Intermezzo will be a durable asset -- we estimate the royalty on Intermezzo alone is worth $10-$11/share."

For an analyst ratings summary and ratings history on Transcept Pharmaceuticals click here. For more ratings news on Transcept Pharmaceuticals click here.

Shares of Transcept Pharmaceuticals closed at $6.74 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Add Your Comment